BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist. 2011;4:55-64. [PMID: 21694909 DOI: 10.2147/idr.s4188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis. World J Gastroenterol 2013; 19(39): 6665-6678 [PMID: 24151397 DOI: 10.3748/wjg.v19.i39.6665] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
2 Liang J, Jiang MJ, Deng X, Xiao Zhou X. Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study. Hepat Mon. 2013;13:e7862. [PMID: 24032045 DOI: 10.5812/hepatmon.7862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
3 Liu K, Xiang X, Bao R, Chen R, Liu Y, Xie J, Guo Q, Bao S, Xie Q, Wang H. A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients. Sci Rep 2016;6:28779. [PMID: 27364728 DOI: 10.1038/srep28779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Cho EJ, Yu SJ, Kwon SY, Kim JH, Kim DY, Kim W, Lee JS, Lee JW, Lee YJ, Chae HB, Yoon JH. Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. Drug Des Devel Ther 2018;12:3767-74. [PMID: 30464407 DOI: 10.2147/DDDT.S181561] [Reference Citation Analysis]
5 Qiu Q, Li Y, Duan XW, Yang LK, Chen Y, Li H, Wang L, Duan ZP. Impact of a new reimbursement program on hepatitis B antiviral medication cost and utilization in Beijing, China. PLoS One 2014;9:e109652. [PMID: 25329072 DOI: 10.1371/journal.pone.0109652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
6 Luo A, Jiang X, Ren H. Entecavir-based combination therapies for chronic hepatitis B: A meta-analysis. Medicine (Baltimore) 2018;97:e13596. [PMID: 30572464 DOI: 10.1097/MD.0000000000013596] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Bivigou-Mboumba B, Amougou-Atsama M, Zoa-Assoumou S, M'boyis Kamdem H, Nzengui-Nzengui GF, Ndojyi-Mbiguino A, Njouom R, François-Souquière S. Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence. PLoS One 2018;13:e0190592. [PMID: 29315352 DOI: 10.1371/journal.pone.0190592] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
8 Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Int J Med Sci. 2013;10:427-433. [PMID: 23471472 DOI: 10.7150/ijms.5472] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
9 Kwon DH, Kim IH, Choung BS, Ahn DS, Yoo SH, Park SB, Lee S, Kim SH, Kim SW, Im YJ. Continuous long-term entecavir therapy in naïve chronic hepatitis B patients showing partial virologic response. Gut Liver 2013;7:712-8. [PMID: 24312713 DOI: 10.5009/gnl.2013.7.6.712] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
10 Chakkor A, Rouibaa F, Elaboudi S, Aourarh A. An evaluation of entecavir treatment among nucleos(t)ide-naïve Moroccan patients with chronic hepatitis B. BMJ Open Gastroenterol 2016;3:e000081. [PMID: 27195127 DOI: 10.1136/bmjgast-2016-000081] [Reference Citation Analysis]